DOA Stock Overview
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Soligenix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.85 |
| 52 Week High | US$14.11 |
| 52 Week Low | US$5.58 |
| Beta | 1.74 |
| 1 Month Change | 0% |
| 3 Month Change | -5.11% |
| 1 Year Change | -10.53% |
| 3 Year Change | -73.29% |
| 5 Year Change | -71.94% |
| Change since IPO | -77.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| DOA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 1.1% |
| 1Y | -10.5% | -23.5% | 1.9% |
Return vs Industry: DOA exceeded the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: DOA underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| DOA volatility | |
|---|---|
| DOA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: DOA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DOA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 14 | Christopher Schaber | www.soligenix.com |
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer.
Soligenix, Inc. Fundamentals Summary
| DOA fundamental statistics | |
|---|---|
| Market cap | €7.89m |
| Earnings (TTM) | -€12.59m |
| Revenue (TTM) | €865.50k |
9.1x
P/S Ratio-0.6x
P/E RatioIs DOA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DOA income statement (TTM) | |
|---|---|
| Revenue | US$948.91k |
| Cost of Revenue | US$550.82k |
| Gross Profit | US$398.09k |
| Other Expenses | US$14.20m |
| Earnings | -US$13.80m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.45 |
| Gross Margin | 41.95% |
| Net Profit Margin | -1,454.12% |
| Debt/Equity Ratio | -400.6% |
How did DOA perform over the long term?
See historical performance and comparison